Literature DB >> 15978334

Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study.

Panayiotis A Kyzas1, Dimitrios Stefanou, Anna Batistatou, Niki J Agnantis.   

Abstract

Numerous studies indicate the importance of hypoxia-induced pathway in tumor angiogenesis, but in vivo studies examining the importance of this mechanism in prognosis of patients with head and neck squamous cell carcinoma present conflicting results. We performed a retrospective analysis of 81 patients with head and neck squamous cell carcinoma in order to investigate whether hypoxia-inducible factor 1a (HIF-1a) immunohistochemical expression correlates with vascular endothelial growth factor (VEGF) expression and clinicopathologic parameters or prognosis. Our results showed a statistically significant association between HIF-1a and VEGF expression in tumors located in the lower lip and in larynx, but not in those located in the oral cavity. HIF-1a expression had no impact on prognosis, while VEGF expression correlated significantly with adverse prognosis. These findings support the hypothesis that tumor angiogenesis is close related, but not strictly dependent, on the hypoxic conditions of tumor's microenvironment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15978334     DOI: 10.1016/j.canlet.2004.11.060

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Silencing of hypoxia-inducible factor-1α promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2.

Authors:  Zhong-Yang Ding; Yun-Juan Huang; Jian-Dong Tang; Gan Li; Pan-Qiang Jiang; Hao-Tian Wu
Journal:  Exp Ther Med       Date:  2016-10-20       Impact factor: 2.447

2.  Relative quantitative expression of hypoxia-inducible factor-1α, -2α and -3α, and vascular endothelial growth factor A in laryngeal carcinoma.

Authors:  Todor Miroslavov Popov; Teodora Goranova; Gergana Stancheva; Radka Kaneva; Tihomir Dikov; Ivan Chalakov; Julian Rangachev; Dimitar Konov; Spiridon Todorov; Orlin Stoyanov; Vanio Mitev
Journal:  Oncol Lett       Date:  2015-03-24       Impact factor: 2.967

3.  Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Niki J Agnantis; Dimitrios Stefanou
Journal:  Virchows Arch       Date:  2006-04-13       Impact factor: 4.064

Review 4.  Clinical biomarkers for hypoxia targeting.

Authors:  Quynh-Thu Le; Don Courter
Journal:  Cancer Metastasis Rev       Date:  2008-09       Impact factor: 9.264

5.  Role of hyaluronan in angiogenesis and its utility to angiogenic tissue engineering.

Authors:  Erin L Pardue; Samir Ibrahim; Anand Ramamurthi
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

6.  Hypoxia in head and neck squamous cell carcinoma.

Authors:  John Zenghong Li; Wei Gao; Jimmy Yu-Wai Chan; Wai-Kuen Ho; Thian-Sze Wong
Journal:  ISRN Otolaryngol       Date:  2012-10-16

7.  HIF-1α effects on angiogenic potential in human small cell lung carcinoma.

Authors:  Jun Wan; Huiping Chai; Zaicheng Yu; Wei Ge; Ningning Kang; Wanli Xia; Yun Che
Journal:  J Exp Clin Cancer Res       Date:  2011-08-15

8.  The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas.

Authors:  Sittichai Koontongkaew
Journal:  J Cancer       Date:  2013-01-01       Impact factor: 4.207

9.  Oxygen metabolism in oral cancer: HIF and GLUTs (Review).

Authors:  Karuza Maria Alves Pereira; Filipe Nobre Chaves; Thales Salles Angelim Viana; Francisco Samuel Rodrigues Carvalho; Fábio Wildson Gurgel Costa; Ana Paula Negreiros Nunes Alves; Fabrício Bitu Sousa
Journal:  Oncol Lett       Date:  2013-06-03       Impact factor: 2.967

10.  Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression.

Authors:  Jian Ye; Yufeng Yao; Qixue Song; Sisi Li; Zhenkun Hu; Yubing Yu; Changqing Hu; Xingwen Da; Hui Li; Qiuyun Chen; Qing K Wang
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.